Encoded Therapeutics Reports Strong ETX101 Results
SOUTH SAN FRANCISCO, Calif. – May 13, 2026 Encoded Therapeutics presented expanded clinical data from its ongoing POLARIS Phase...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SOUTH SAN FRANCISCO, Calif. – May 13, 2026 Encoded Therapeutics presented expanded clinical data from its ongoing POLARIS Phase...
SOUTH SAN FRANCISCO, Calif., April 27, 2026 Encoded Therapeutics announced its participation in the 29th Annual Meeting of the...
